Prospective evaluation of genomics-guided off-label treatment
Over the past nine years, DRUP provided opportunities for off-label treatment to more than 1,600 patients with advanced…
Praxis Precision Medicines Announces FDA Acceptance and Priority Review of New Drug Application for Relutrigine in Patients with SCN2A and SCN8A DEEs
Praxis Precision Medicines, Inc. FDA assigned PDUFA target action date of September 27, 2026 BOSTON, March 30, 2026…
mRNA Therapeutics CDMO Strategic Research 2025
Dublin, Aug. 29, 2025 (GLOBE NEWSWIRE) — The “mRNA Therapeutics Contract Development & Manufacturing Organization – Global Strategic…